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life expectancy (QALE), cumulative complication incidences and
total management costs (drug costs plus complications) over 10
years. The model combined a series of interdependent time- and
state-based Markov sub-models of diabetes-related complica-
tions, incorporating 2nd order Monte-Carlo simulation. Future
outcomes were discounted at 3% per annum (US Medicare per-
spective). Sensitivity analyses were performed. RESULTS: At
follow-up, HbA1C was reduced 0.59% from baseline, fasting
blood glucose (FBG) was more tightly controlled (−25 mg/dL),
with mean weight loss of 0.78 kg. Daily dose remained stable
upon replacing glargine (27.3 U vs. 23.8 U). Rate of all hypo-
glycaemia decreased by 728 events per 100 patient years from
baseline, with major and nocturnal reduced by 26 and 208
events/100 patient years, respectively. Long-term projections
indicated these clinical beneﬁts increased LYG (0.07 years) and
QALE (0.31 years). Direct medical costs were $2020 less 
per patient (10 years), largely due to reduced incidence rates 
of complications, predominantly renal and cardiovascular.
CONCLUSION: Patients with type 2 diabetes may experience
clinical outcome beneﬁts when using insulin detemir compared
to glargine. These beneﬁts were projected to reduce treatment
costs and increase QALE through a reduction of diabetes-related
complications.
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OBJECTIVES: Evidence-based measures are necessary in
medical decision-making when comparing modern therapy
options with long-established treatments. As such, data from
naturalistic settings provide important insight to use of such
treatments in actual clinical practice. This study aimed to project
real-life economic and clinical implications of converting type 2
diabetes patients on NPH basal-oral therapy to insulin detemir.
METHODS: Pre-transfer, baseline and end-of-study data for 251
subjects converting from NPH ± orals to detemir ± orals were
analyzed. Patients were an enrolled subgroup of a multi-national,
prospective observational trial (51% male; mean age 61.5 years;
diabetes duration 9 years; HbA1c 7.8%; BMI 30.9 kg/m2). Total
treatment costs (annual drug plus complications), life years
gained (LYG), quality-adjusted life expectancy (QALE), and
cumulative complication incidences were assessed using a vali-
dated model of diabetes-related complications. Fifteen intercon-
nected Markov sub-models employed second order Monte Carlo
simulation and non-parametric bootstrapping (1000 × 1000) to
estimate long-term outcomes (10 year horizon; US Medicare per-
spective), discounted at 3% per annum. Sensitivity analyses were
performed. RESULTS: At 12 weeks post-transfer, mean absolute
HbA1c was reduced 0.58%, with improved fasting blood
glucose (−28 mg/dL) and weight reduction (0.87 kg). Observa-
tion period daily dose did not differ considerably to pre-transfer
NPH (27.8 U vs. 25.7 U). Use of orals remained similar upon
conversion. A reduced rate of all hypoglycaemia (pre- vs. post-
transfer) was observed (−663 events/100 patient years), as were
major and nocturnal episodes (39 and 429 events/100 patient
years, respectively). Clinical beneﬁts led to projected increases in
LYG (0.07 years) and QALE (0.30 years), with associated total
management costs reduced $2416 per patient, primarily from
reductions in major hypoglycaemia and complication risks
(notably ocular and cardiovascular). CONCLUSION: Improved
glycaemic control and reduced hypoglycaemia were observed 
in patients with type 2 diabetes transferring from NPH-based
therapy to detemir, generating projected improvements in
quality-adjusted life expectancy and total costs.
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OBJECTIVES: Many patients with type 2 diabetes are not
achieving recommended HbA1c targets. Barriers preventing the
initiation of more efﬁcacious therapies include economic restric-
tions. The present analysis aimed to evaluate potential clinical
and economic outcomes of initiating insulin detemir among type
2 diabetes patients previously on oral medication alone.
METHODS: Data were analyzed from 1321 patients who par-
ticipated in a 12-week prospective observational trial (50.6%
male; mean age 62.2 years; diabetes duration 6.5 years; HbA1c
8.49%; BMI 29.5 kg/m2). A published and validated simulation
model of diabetes projected total treatment costs (annual drug
plus complications), life years gained (LYG), quality-adjusted life
expectancy (QALE), and complication incidences for patients
commencing detemir versus those modelled to remain insulin
naïve (10 year horizon). The model structure combines 15 inter-
dependent Markov sub-models, simulating the progression of
diabetes-related complications and utilizing second order Monte
Carlo simulation to account statistical uncertainty at the patient
and parameter levels. Outcomes were discounted at 3% per
annum (US Medicare perspective). Sensitivity analyses were 
performed. RESULTS: Initiation of detemir generated a 1.29%
mean reduction in HbA1c over 3 months, with improved fasting
blood glucose (FBG; total (SD): −58 mg/dL (−8.2 mg/dL)), and
no signiﬁcant increase in the occurrence of hypoglycaemia. At
follow-up, 16% of patients discontinued or reduced oral med-
ications. Pharmacoeconomic modelling demonstrated detemir
treatment to improve LYG (0.156 years) and QALE (0.173
years). Reduced major complication incidences were also esti-
mated, including vascular, ocular, and renal events. An incre-
mental cost-effectiveness ratio (ICER) of $657 per QALY gained
was generated. An acceptability curve (willingness-to-pay of
$50,000/QALY) revealed detemir to have a 95.5% chance of
being cost-effective. CONCLUSION: Considerable short-term
clinical beneﬁts were observed among insulin-naïve type 2
patients initiating detemir. Long-term treatment with detemir
was predicted to increase quality-adjusted outcomes and reduce
diabetic complications in a cost-effective manner.
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OBJECTIVES: The US NHANES study reveals that most type 
2 diabetes patients are not achieving endorsed HbA1c goals.
During disease progression, clinicians treating insulin-naïve sub-
jects may optimize continued oral therapy, or prescribe exoge-
nous insulin to induce tighter glycaemic control. The present
analysis aimed to estimate long-term clinical and economic out-
